" class="no-js "lang="en-US"> Kite - Medtech Alert
Thursday, September 11, 2025
Kite | Pharmtech Focus

Kite

About Kite

Kite

Kite, a Gilead Company, is dedicated to achieving one of the most ambitious goals of 21st century medicine: curing cancer. This mission is at the heart of everything we do, from early research to product development.

For the past three decades, members of our team have been at the forefront of cancer immunotherapy. Today, we are a leader in engineered T cell therapy, changing the paradigm of cancer treatment with what is potentially the biggest breakthrough since the introduction of combination chemotherapy more than 60 years ago.

With an unrelenting drive and a singular focus on cell therapy, our team is executing on our strategy to bring life-saving therapies to patients.

In all areas of the company, we are looking for the very best people who share our deep passion to cure cancer. We realize that our ambitious goals can only be achieved if every employee is fully committed to our mission and embraces our entrepreneurial spirit. If this describes you, please contact us.

Our corporate headquarters are in Santa Monica, California.

Related Story

Kite to Acquire Tmunity Therapeutics to Pursue Next Generation CAR T-Cell Therapy Advancements in Cancer

December 20 2022

Kite and Tmunity Therapeutics have announced that the companies have signed an agreement in which […]

Gilead and Kite Oncology Demonstrate Broad Leadership in Cell Therapy and Expanding Blood Cancer Pipeline

November 5 2021

Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, today announced that data at […]

BioNTech Completes Acquisition of Kite’s Neoantigen TCR Cell Therapy R&D Platform and Manufacturing Facility in Gaithersburg, Maryland

August 5 2021

BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Kite, a Gilead Company (Nasdaq: GILD, “Kite”) today announced the closing […]